The biotech sector could rebound this year, with intact fundamentals and a pipeline that "remains as rich as ever," the firm wrote in a note, Barron's reports. Biotech's growth, which importantly is driven mostly by revenues, remains above that of the broader markets and of pharma.
Risk tolerance has declined, and most of the stocks are trading at very little to no value to pipeline, the firm continued. Pricing is unlikely to change in the near future.
Additionally, biotech looks as if it is nearing a bottom, as weakness since July has been greater than weakness during 2008, according to Citigroup, Barron's notes.
Based in Foster City, CA, Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Gilead's strengths such as its robust revenue growth, notable return on equity, attractive valuation levels, impressive record of earnings per share growth and compelling growth in net income outweigh the fact that the company has had lackluster performance in the stock itself.
You can view the full analysis from the report here: GILD
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.